Heterodimerization of sGC catalytic domains is necessary but insufficient for full activity, revealing a novel regulatory mechanism that could guide the design of new drugs targeting the NO-sGC-cGMP pathway.
No takes yet. Share an insight, caveat, or question.
Preclinical sGC data require intact domains for activity models; leaves open translation to NO-sGC-cGMP drug design.
Seeger et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: